PAMU
CLVS

Pictet Asset Management (UK)’s Clovis Oncology, Inc. CLVS Stock Holding History

Pictet Asset Management (UK)’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$63K Hold
10,800
– – ﹤0.01% 1730
2021
Q1 		$76K Hold
10,800
– – ﹤0.01% 1760
2020
Q4 		$52K Hold
10,800
– – ﹤0.01% 1731
2020
Q3 		$63K Buy
+10,800
New +$64.6K ﹤0.01% 1526
2019
Q4 		– Sell
-188,000
Closed -$739K – 1148
2019
Q3 		$739K Buy
188,000
+6,900
+4% +$55.8K ﹤0.01% 942
2019
Q2 		$2.69M Buy
181,100
+35,300
+24% +$638K 0.01% 824
2019
Q1 		$3.62M Buy
145,800
+48,300
+50% +$1.21M 0.01% 765
2018
Q4 		$1.75K Buy
97,500
+21,600
+28% +$441K ﹤0.01% 846
2018
Q3 		$2.23M Sell
75,900
-307,134
-80% -$11.9M ﹤0.01% 878
2018
Q2 		$17.4M Buy
383,034
+49,104
+15% +$2.39M 0.04% 424
2018
Q1 		$17.6M Sell
333,930
-65,804
-16% -$3.84M 0.04% 403
2017
Q4 		$27.2M Buy
399,734
+32,705
+9% +$2.29M 0.07% 326
2017
Q3 		$30.2M Buy
367,029
+51,366
+16% +$4.07M 0.09% 290
2017
Q2 		$16.3M Buy
315,663
+128,852
+69% +$7.88M 0.05% 390
2017
Q1 		$11.9M Sell
186,811
-8,474
-4% -$515K 0.04% 448
2016
Q4 		$8.68M Buy
+195,285
New +$6.87M 0.03% 474
2015
Q3 		– Sell
-17,200
Closed -$1.45M – 900
2015
Q2 		$1.45M Sell
17,200
-4,800
-22% -$411K 0.01% 774
2015
Q1 		$1.77M Sell
22,000
-51,533
-70% -$3.64M 0.01% 761
2014
Q4 		$4.12M Buy
+73,533
New +$3.86M 0.02% 625
2014
Q3 		– Sell
-27,900
Closed -$1.16M – 895
2014
Q2 		$1.16M Sell
27,900
-3,200
-10% -$165K 0.01% 778
2014
Q1 		$2.15M Sell
31,100
-3,900
-11% -$286K 0.01% 729
2013
Q4 		$2.11M Buy
35,000
+8,100
+30% +$441K 0.01% 728
2013
Q3 		$1.64M Buy
26,900
+12,200
+83% +$865K 0.01% 750
2013
Q2 		$985K Buy
+14,700
New +$661K 0.01% 771

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pictet Asset Management (UK)'s CLVS Position: Q2 2021 in Review

Pictet Asset Management (UK) held its Clovis Oncology, Inc. (CLVS) position steady in Q2 2021 at 10,800 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

Pictet Asset Management (UK) first reported a position in CLVS in Q2 2013 and has held it in 24 quarters since. The position peaked at $30.2M in Q3 2017. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Pictet Asset Management (UK) held 10,800 shares of Clovis Oncology, Inc. worth $63K as of Q2 2021.
  • Pictet Asset Management (UK) left its Clovis Oncology, Inc. share count unchanged in Q2 2021.
  • Clovis Oncology, Inc. made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1730 holding.
  • Pictet Asset Management (UK) first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 24 quarters since.
  • Pictet Asset Management (UK)'s Clovis Oncology, Inc. position peaked at $30.2M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.